Are There Experimental Treatments for Sjögren-Larsson?

Currently, there is no approved cure for Sjögren-Larsson syndrome (SLS), and standard care focuses heavily on managing symptoms like skin scaling (ichthyosis) and muscle stiffness (spasticity). However, researchers are actively developing and testing experimental treatments that aim to address the root cause of the condition ^[1]. Because SLS is caused by a deficiency in the fatty aldehyde dehydrogenase (FALDH) enzyme, toxic fatty aldehydes and alcohols accumulate in the body ^[2][3]. New therapies aim to trap these toxic substances, bypass the broken enzyme, or fix the underlying genetic mutation ^[1][2].

While these therapies are still in various stages of testing, they offer hope for treatments that could slow or halt the progression of the disease rather than just treating its symptoms.

Aldehyde-Scavenging Drugs (Aldehyde Traps)

One of the most promising areas of clinical research involves aldehyde-scavenging drugs, such as reproxalap (also known as ADX-102 and sometimes referred to as reproxin) ^[2]. Because the FALDH enzyme cannot break down fatty aldehydes, these molecules build up and form harmful compounds (adducts) that damage cells in the skin, brain, and eyes ^[2].

Aldehyde scavengers act as “chemical traps.” They bind directly to the reactive fatty aldehydes, neutralizing them before they can form toxic compounds ^[2].

• Preclinical success: In laboratory models of SLS, these drugs have successfully protected cells from toxicity and reduced the accumulation of harmful substances ^[2].
• Clinical trials for skin symptoms: A Phase 2 clinical trial (a study to evaluate safety and effectiveness in a small group of patients) tested a topical ointment version of these aldehyde-trapping drugs to see if they could improve the severe skin symptoms of SLS ^[1][2].
• What about the brain? Because the trial used a topical cream applied to the skin, it was not designed to treat the severe neurological symptoms (like spasticity and developmental delays). Whether an oral or intravenous version of these drugs could safely cross the “blood-brain barrier” to protect the brain remains a critical question for future research.
• Current status: While this specific SLS trial was completed, it is not currently recruiting new patients. The drug manufacturer has recently focused on using reproxalap for eye conditions like dry eye disease ^[4][5]. However, this mechanism remains a key proof-of-concept for treating the metabolic defect in SLS.

PPAR-alpha Agonists: Bypassing the Missing Enzyme

Since the primary FALDH enzyme is defective in SLS, researchers are looking for ways to force the body to use alternative enzymes to do the same job. This is known as “bypass” therapy.

PPAR-alpha agonists (a class of drugs that includes medications like fibrates, which are commonly used to lower cholesterol) are being investigated for this purpose ^[1]. These drugs may stimulate the activity of other aldehyde dehydrogenase enzymes in the body ^[1]. The hope is that if these backup enzymes are activated, they can step in and clear the toxic fatty aldehydes that the missing FALDH enzyme left behind.

A note on off-label use: Because fibrates are already approved for other conditions, some parents wonder if doctors prescribe them “off-label” for SLS. Currently, this approach is strictly experimental and not standard practice, but it is a valid topic to discuss with your child’s metabolic specialist.

Gene Therapy: Targeting the Root Cause

The ultimate goal for treating genetic disorders like SLS is gene therapy, which aims to provide the body with a working copy of the mutated ALDH3A2 gene ^[2][1]. If cells receive a functional gene, they can produce their own working FALDH enzyme, potentially curing the disease or significantly halting its progression.

Currently, gene therapy for SLS is in the preclinical stage ^[6][1]. This means it is being tested in laboratories using cellular models (like stem cells derived from patients) and animal models (like mice engineered to have SLS) ^[6][7]. Researchers are exploring how to use specialized delivery systems to safely get the functional gene past the blood-brain barrier and into the brain and skin cells that need it most. While human clinical trials for gene therapy have not yet begun for SLS, this early research lays the groundwork for future curative treatments.

Other Emerging Approaches

Scientists are also exploring other experimental pathways, including:

• Alternative enzyme introduction: Researchers are studying whether alternative enzymes from other organisms could be introduced to help clear the excess fatty aldehydes ^[8].
• JNK inhibitors and antioxidants: Researchers are looking into drugs that block specific inflammatory pathways or reduce the oxidative stress caused by the lipid buildup ^[1][2]. (Note: This research involves specific, experimental pharmaceutical compounds. Parents should not start giving children over-the-counter antioxidant supplements without consulting a doctor, as high doses can be dangerous or interfere with other medications.)

Participating in Clinical Trials

Because SLS is an ultra-rare disease, clinical trials often struggle to find enough participants. Participating in a trial gives patients access to emerging therapies, but it comes with significant commitments. Trials for rare diseases often require frequent travel to specialized research universities or tertiary care centers, which can be a heavy logistical burden for a family managing severe mobility challenges. Furthermore, the safety and effectiveness of experimental drugs are not yet fully understood.

Parents interested in trials should:

• Maintain open communication with a pediatric metabolic specialist or geneticist who specializes in neurocutaneous syndromes.
• Regularly check registries like ClinicalTrials.gov. Try searching for terms like “Sjogren-Larsson syndrome”, “ALDH3A2”, or “fatty aldehyde dehydrogenase deficiency”.
• Ask your doctor about participating in “Natural History Studies,” which don’t test a drug but track how the disease progresses over time. These are vital for proving that a new experimental drug actually works in future trials.